While PI3K inhibitors are known to be effective in HR-positive, HER2-negative breast cancer, with alpelisib currently FDA-approved in this setting, these drugs are not currently used for HER2-positive breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.